LUNGevity Foundation
BJ Jones is the Chief Commercial Officer, Migraine and Common Disease, at Biohaven Pharmaceuticals, where he is responsible for creating a vertically integrated commercial team from concept to deployment in ten months.
With over 25 years of commercial experience in the healthcare industry, BJ has held leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and NitroMed. He has significant experience in mass market product launches and has successfully built and lead diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience, cardio-metabolic, respiratory, GI, and infectious disease.
Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major. He provided threat assessments to NATO leadership as an Engineering Analyst in the Foreign Technology division and led cutting-edge research in the Artificial Intelligence in Training program as a Function Chief in the AF Human Systems Division.
He holds a BS in Human Factors Engineering from the U.S. Air Force Academy, an MS in Industrial Engineering from Texas A&M University, and an MBA from Stanford Graduate School of Business.
This person is not in the org chart
This person is not in any offices
LUNGevity Foundation
2 followers
LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, policy initiatives, education, support, and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivors—and those who help them live longer and better lives.